Type 2 diabetes patients enrolled in the trial will be on stable metformin therapy and will receive monthly treatment for six months with one of four doses ...
For every 1-g increase in metformin dose, the risk for cancer mortality decreased by 42% (HR=0.58; 95% CI, 0.36-0.93). The researchers concluded that ...
... while 39 of the study participants were treated with a daily dose of 2000 milligrams of metformin hydrochlorideXR, and the other 38 were given a placebo ...
... of physical activity and diet) and either one daily dose of metformin XR (2000 milligrams) (39 patients) or placebo (38 patients) for 48 weeks. ...
Some received a placebo, while others got a daily dose of 2000 milligrams of metformin XR. Over a year, the average body-mass index -- a measurement of ...
... for a fixed dose combination of ONGLYZA(R) (saxagliptin) plus metformin HCl extended-release tablets. The FDA is currently reviewing the submission. ...
... with: Metformin or a sulphonylurea in patients with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin or ...
... and electrophysiological measures (two scoring systems and nerve conduction studies), which was strongly associated with cumulative metformin dose. ...
... extended release technology to Merck & Co., Inc. to be used in developing fixed dose combinations of sitagliptin and extended release metformin. ...
Email this story
